Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 2/20 | 0.37 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.37 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4043614 | 0.92 | CTSK (0.44) | CTSKPOLBHPGDALDH1A1CHRNB2 | |
| SCHEMBL4046945 | 0.92 | CTSK (0.55) | CTSKCTSSPOLBALDH1A1CHRNB2 | |
| SCHEMBL4042601 | 0.91 | CTSK (0.54) | CTSKCTSSPOLBALDH1A1CHRNB2 | |
| SCHEMBL4042595 | 0.91 | CTSK (0.57) | CTSKCTSSPOLBALDH1A1CHRNB2 | |
| SCHEMBL4042794 | 0.90 | CTSK (0.57) | CTSKCTSSALDH1A1ACEHTRA1 | |
| SCHEMBL4044197 | 0.90 | CTSK (0.63) | CTSKCTSSCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL4039907 | 0.89 | CTSK (0.59) | CTSKCTSSACEGPR132 | |
| SCHEMBL4047037 | 0.89 | CTSK (0.56) | CTSKCTSSPOLBALDH1A1ACE | |
| SCHEMBL4041333 | 0.88 | CTSK (0.69) | CTSKCTSSHPGDALDH1A1ACE | |
| SCHEMBL4046389 | 0.88 | CTSK (0.69) | CTSKCTSSALDH1A1CHRNB2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885CTSS 3/4885POLB 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.